[STUDY OF THE ACTION OF NALIDIXIC ACID IN URINARY INFECTIONS].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In a bacteriologic and clinical assessment of nalidixic acid (NegGram), 95% of Gramnegative urinary pathogens tested in vitro (with the exception of Pseudomonas pyocyanea) were sensitive to therapeutically attainable levels. The antibacterial spectrum of this agent was surpassed only by parenteral kanamycin, which is potentially ototoxic. Of 70 patients treated with 0.5-1.0 g. every six hours for from two weeks to two months, 61 underwent a full course of treatment and could be assessed. In 42 the infection cleared up, in 15 the original organism disappeared and a new resistant organism emerged, and in four the original organisms became resistant. These four were treated with 0.5 g. every six hours, which suggests that the higher dose may be necessary to prevent development of resistance. In only three of 13 patients with nausea did the drug have to be discontinued. Two patients developed drug rashes and one diarrhea. The drug is a valuable addition to the therapeutic agents used for urinary infections.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.